Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This 'Alpha-1 Antitrypsin ...

Researchers have identified alpha-1 antitrypsin deficiency (AATD) ... If 16.4 million people in the United States have COPD, roughly 164,000 to 656,000 people have AATD.

Alpha-1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. ... In the United States, ...

Alpha-1 Antitrypsin Deficiency Companies are Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk, and others. (Albany, USA) DelveInsight ...

Prime Editing is positioned as a potentially best-in-class approach for treating alpha-1 antitrypsin deficiency ... for the approximately 200,000 people in the United States and European ...

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug ...

Background: Influenza vaccination is recommended for all subjects with COPD, including α 1-antitrypsin deficiency (AATD), but immunization practices are below US national goals. Influenza ...

Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from an ongoing early to mid-stage study of its investigational candidate ...

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This 'Alpha-1 Antitrypsin ...

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE ...